cl 387785 has been researched along with ekb 569 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ | 1 |
| Abou El Ella, DA; Aly, RM; El-Motwally, AM; Ibrahim, DA | 1 |
| Attram, HD; Chibale, K; Dziwornu, GA; Gachuhi, S | 1 |
| Discafani, CM; Frost, P; Jackson, PE; Kinzler, KW; Montgomery, E; Nunes, M; Torrance, CJ; Vogelstein, B; Wissner, A | 1 |
| Avner, ED; Frost, P; Harris, PC; Qian, Q; Sweeney, WE; Torres, VE; Wang, X | 1 |
1 review(s) available for cl 387785 and ekb 569
| Article | Year |
|---|---|
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
Topics: | 2020 |
4 other study(ies) available for cl 387785 and ekb 569
| Article | Year |
|---|---|
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship | 2013 |
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship | 2015 |
Combinatorial chemoprevention of intestinal neoplasia.
Topics: Adenomatous Polyposis Coli; Aminoquinolines; Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Mice; Mice, Mutant Strains; Organic Chemicals; Quinazolines; Sulindac | 2000 |
Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.
Topics: Aminoquinolines; Aniline Compounds; Animals; Cyclic AMP; Disease Models, Animal; ErbB Receptors; Female; Injections, Intraperitoneal; Intubation, Gastrointestinal; Kidney; Male; Organic Chemicals; Polycystic Kidney, Autosomal Recessive; Quinazolines; Rats; Rats, Inbred Strains; Rats, Sprague-Dawley; Receptors, Vasopressin; Severity of Illness Index | 2004 |